About Unicycive
Unicycive is a company based in San Francisco (United States) founded in 2016.. Unicycive has raised $1.55 million across 5 funding rounds from investors including Octagon Capital Advisors, Great Point Partners and Logos Capital. The company has 22 employees as of December 31, 2024. Unicycive offers products and services including Oxylanthanum Carbonate (OLC) and UNI-494. Unicycive operates in a competitive market with competitors including Calliditas Therapeutics, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
- Headquarter San Francisco, United States
- Employees 22 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Unicycive Therapeutics, Inc.
-
Annual Revenue
$0-100as on Dec 31, 2024
-
Net Profit
$-36.73 M-20.25as on Dec 31, 2024
-
EBITDA
$-31.69 M-54.66as on Dec 31, 2024
-
Total Equity Funding
$1.55 M (USD)
in 5 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Mar 13, 2024
-
Investors
Octagon Capital Advisors
& 6 more
-
Employee Count
22
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Unicycive
Unicycive is a publicly listed company on the NASDAQ with ticker symbol UNCY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Unicycive
Unicycive offers a comprehensive portfolio of products and services, including Oxylanthanum Carbonate (OLC) and UNI-494. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats hyperphosphatemia using proprietary nanoparticle technology.
Targets mitochondria for acute kidney injury treatment.
Unlock access to complete
Funding Insights of Unicycive
Unicycive has successfully raised a total of $1.55M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(04 Mar 2019)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Unicycive | Valuation |
investors |
|
| Mar, 2023 | Amount | Post-IPO - Unicycive | Valuation |
investors |
|
| Jun, 2020 | Amount | Seed - Unicycive | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Unicycive
Unicycive has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Octagon Capital Advisors, Great Point Partners and Logos Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on company buyouts
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Unicycive
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Unicycive
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Unicycive Comparisons
Competitors of Unicycive
Unicycive operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Therapeutics for renal diseases are developed and launched by Renalys.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Unicycive
Frequently Asked Questions about Unicycive
When was Unicycive founded?
Unicycive was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Where is Unicycive located?
Unicycive is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Unicycive a funded company?
Unicycive is a funded company, having raised a total of $1.55M across 5 funding rounds to date. The company's 1st funding round was a Seed of $604.14K, raised on Mar 04, 2019.
How many employees does Unicycive have?
As of Dec 31, 2024, the latest employee count at Unicycive is 22.
What does Unicycive do?
Unicycive was founded in 2016 and is based in San Francisco, United States. Focus is placed on developing small molecule therapies targeting kidney diseases within the biotechnology sector. The lead product, UNI 494, is under investigation for both acute and chronic kidney conditions. Oxylanthanum Carbonate is also being advanced for managing hyperphosphatemia. Operations center on therapeutic innovation for renal health challenges.
Who are the top competitors of Unicycive?
Unicycive's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
What products or services does Unicycive offer?
Unicycive offers Oxylanthanum Carbonate (OLC) and UNI-494.
Is Unicycive publicly traded?
Yes, Unicycive is publicly traded on NASDAQ under the ticker symbol UNCY.
Who are Unicycive's investors?
Unicycive has 7 investors. Key investors include Octagon Capital Advisors, Great Point Partners, Logos Capital, Nantahala Capital Management, and Velan Capital.
What is Unicycive's ticker symbol?
The ticker symbol of Unicycive is UNCY on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.